EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:


	•		Forms S-3 (File No. 333-262551, 333-283307 and 333-284222) of Inhibikase Therapeutics, Inc.,


	•		Forms S-8 (File No. 333-259555 and 333-284687) pertaining to the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan of Inhibikase Therapeutics, Inc., and


	•		Forms S-1 (File No. 333-269521 and 333-280317) of Inhibikase Therapeutics, Inc.

of our report dated March 27, 2025, with respect to the consolidated financial statements of Inhibikase Therapeutics, Inc. and Subsidiary included in this Annual Report (Form 10-K) of Inhibikase Therapeutics, Inc. and Subsidiary for the years ended December 31, 2024 and December 31, 2023.

    /s/ CohnReznick LLP

   

    Holmdel, New Jersey

   

    March 27, 2025

   